Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators
Industry's Request For A Standardized Approach Has Been Set Aside
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
